SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

June 13, 2016 07:00 ET

CTD Holdings Lead Director Markus W. Sieger Named CEO of Polpharma

Polpharma Is a Large Pharmaceutical Group Focusing on Generics and Biosimilars in Central and Eastern Europe

ALACHUA, FL--(Marketwired - June 13, 2016) - CTD Holdings (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that its Lead Director, Mr. Markus W. Sieger of Zürich, Switzerland, has been named Chief Executive Officer of Polpharma Group (www.polpharma.com) with executive offices in Warsaw, Poland.

Polpharma is the leading Polish generics producer, operating across Europe, the Caucasus and Central Asia, with manufacturing subsidiaries in Poland, Russia and Kazakhstan and annual sales of nearly $1 billion. It is also one of the leading European API producers, delivering products for pharmaceutical companies worldwide. In order to provide patients with more affordable access to modern biologic drugs, Polpharma has decided to invest in biosimilar products. It has therefore created a state-of-the-art R&D and production center and established strategic partnerships to expand its capabilities of biosimilars on a global scale.

"We congratulate our colleague Markus Sieger in his new position as CEO of Polpharma," said CTD Chairman and CEO N. Scott Fine. "His knowledge of the pharmaceutical industry, coupled with his passion to improve the health of people globally, will benefit Polpharma as they continue to benefit CTD."

About the Company:
CTD Holdings, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company's website: www.ctd-holdings.com

Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information